In a previous study, Lim et al. reported that helenalin was able to increase the levels of cleaved caspase 3, caspase 9 and PARP in a dose- and time-dependent manner in ovarian, colon and breast cancer cells. This evidence concerns the gene CASP3 and breast carcinoma.